[1]张治业,余醒醒,张 璐,等.CD166对多发性骨髓瘤RPMI-8226细胞增殖、凋亡及自噬的影响实验研究[J].陕西医学杂志,2023,52(12):1675-1679.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
　ZHANG Zhiye,YU Xingxing,ZHANG Lu,et al.Effects of CD166 on proliferation,apoptosis and autophagy of multiple myeloma RPMI-8226 cells[J].,2023,52(12):1675-1679.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
点击复制

CD166对多发性骨髓瘤RPMI-8226细胞增殖、凋亡及自噬的影响实验研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年12期
页码:
1675-1679
栏目:
基础研究
出版日期:
2023-12-05

文章信息/Info

Title:
Effects of CD166 on proliferation,apoptosis and autophagy of multiple myeloma RPMI-8226 cells
作者:
张治业1; 2; 余醒醒1; 张 璐1; 翟志敏2
(1.安徽医科大学附属阜阳医院血液内科,安徽 阜阳 236000; 2.安徽医科大学第二附属医院血液内科,安徽 合肥 230601)
Author(s):
ZHANG Zhiye; YU Xingxing; ZHANG Lu; ZHAI Zhimin
(Department of Hematology,Fuyang Hospital,Anhui Medical University,Fuyang 236000,China)
关键词:
多发性骨髓瘤;  CD166;  增殖;  凋亡;  自噬;  裸鼠
Keywords:
Multiple myeloma;  CD166;  Proliferation;  Apoptosis;  Autophagy;  Nude mouse
分类号:
R 733.3
DOI:
DOI:10.3969/j.issn.1000-7377.2023.12.010
文献标志码:
A
摘要:
目的:探究CD166对多发性骨髓瘤(MM)RPMI-8226细胞增殖、凋亡及自噬的影响。方法:选取MM细胞RPMI-8226,设计并合成靶向CD166的短发夹RNA(shRNA)和阴性对照(NC)进行细胞转染,分为sh-CD166-1组、sh-CD166-2组和NC组。采用MTT法和平板克隆实验观察CD166对RPMI-8226细胞增殖能力和平板克隆形成能力的影响。利用流式细胞仪检测CD166对RPMI-8226细胞凋亡的影响。采用自噬实验观察CD166对RPMI-8226细胞自噬的影响。此外,将BALB/c裸鼠随机分为NC组和sh-CD166组,通过皮下移植瘤模型评估CD166对RPMI-8226细胞体内成瘤能力的影响。结果:sh-CD166转染后,显著抑制RPMI-8226细胞的增殖能力和平板克隆形成能力(均P<0.05)。与NC组比较,sh-CD166-1组和sh-CD166-2组细胞凋亡率升高(均P<0.05),但sh-CD166-1组和sh-CD166-2组比较差异无统计学意义(均P>0.05)。与NC组比较,sh-CD166组细胞中自噬小体表达量明显减少(P<0.05)。此外,体内移植瘤模型结果表明,sh-CD166组体内成瘤能力比NC组显著降低(P<0.05)。结论:CD166能促进MM细胞 RPMI-8226增殖,抑制细胞凋亡,并促进皮下成瘤。
Abstract:
Objective:To investigate the effects of CD166 on the proliferation,apoptosis and autophagy of multiple myeloma(MM)RPMI-8226 cells.Methods:MM RPMI-8226 cells were selected,and CD166-targeting short hairpin RNA(shRNA)and negative control(NC)were designed and synthesize for cell transfection,and cells were divided into sh-CD166-1,Sh-CD166-2 and NC groups.MTT assay and plate cloning assay were used to observe the effects of CD166 on the proliferation ability and plate cloning ability of RPMI-8226 cells.The effect of CD166 on apoptosis of RPMI-8226 cells was detected by flow cytometry.The effect of CD166 on autophagy of RPMI-8226 cells was observed by autophagy experiment.In addition,BALB/c nude mice were randomly divided into NC group and sh-CD166 group,and the effect of CD166 on tumor-forming ability of RPMI-8226 cells was evaluated by subcutaneous tumor transplantation model.Results:After transfection with sh-CD166,the proliferation ability and plate cloning ability of RPMI-8226 cells were significantly inhibited(all P<0.05).Compared with NC group,the apoptosis rate of sh-CD166-1 and sh-CD166-1 groups was increased(all P<0.05),but there was no statistical significance between Sh-CD166-1 and SH-CD166-1 groups(all P>0.05).Compared with NC group,the expression of autophagosome in sh-CD166 group was significantly decreased(P<0.05).In addition,the results of in vivo transplantation tumor model showed that the tumor formation ability of sh-CD166 group was significantly lower than that of NC group(P<0.05).Conclusion:CD166 can promote the proliferation of MM RPMI-8226 cells,inhibit cell apoptosis,and promote subcutaneous tumor formation.

参考文献/References:

[1] Gerecke C,Fuhrmann S,Strifler S,et al.The diagnosis and treatment of multiple myeloma[J].Dtsch Arztebl Int,2016,113(27-28):470-476.
[2] Kazandjian D.Multiple myeloma epidemiology and survival:A unique malignancy[J].Semin Oncol,2016,43(6):676-681.
[3] Siegel RL,Miller KD,Wagle NS,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.
[4] Gay F,Oliva S,Petrucci MT,et al.Chemotherapy plus lenalidomide versus autologous transplantation,followed by lenalidomide plus prednisone versus lenalidomide maintenance,in patients with multiple myeloma:A randomised,multicentre,phase 3 trial[J].Lancet Oncol,2015,16(16):1617-1629.
[5] 杜娟英,薛海鲸.多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J].陕西医学杂志,2022,51(12):1585-1588,1592.
[6] Lersner A,Droesen L,Zijlstra A.Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166[J].Clin Exp Metas,2019,36(2):87-95.
[7] Zhang J,Ghosh J,Mohamad SF,et al.CD166 engagement augments mouse and human hematopoietic progenitor function via activation of stemness and cell cycle pathways[J].Stem Cells,2019,37(10):1319-1330.
[8] Burkhardt M,Mayordomo E,Winzer KJ,et al.Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer[J].J Clin Pathol,2006,59(4):403-409.
[9] Jezierska A,Matysiak W,Motyl T.ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy[J].Med Sci Monitor,2006,12(8):263-273.
[10] 林炳煌,黄荣金,何清安,等.ALCAM/CD166在乳腺癌组织中表达及意义以及其与Bcl-2、Ki-67的关系[J].中国普外基础与临床杂志,2015,22(12):1466-1470.
[11] 崔 兴,徐龙进.干预microRNA-181a调控线粒体自噬促进骨髓瘤细胞凋亡的研究[J].中国医科大学学报,2022,51(1):6-11.
[12] Terpos E,Christoulas D,Kastritis E,et al.VTD consolidation,without bisphosphonates,reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT[J].Leukemia,2014,28(4):928-934.
[13] 王辰辰,张倩倩,李 静,等.化痰活血方治疗痰瘀痹阻型多发性骨髓瘤疗效及对患者血管内皮生长因子的影响[J].陕西中医,2022,43(5):588-591.
[14] 李迎巧,高二超,王茂生.杨淑莲治疗多发性骨髓瘤经验[J].陕西中医,2022,43(5):628-631,652.
[15] Alexanian R,Wang M,Delasalle K,et al.Value of novel agents and intensive therapy for patients with multiple myeloma[J].Bone Marrow Transplantation,2014,49(3):422-425.
[16] 靳娟娟,姚 玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934-936,948.
[17] Kijima N,Hosen N,Kagawa N,et al.CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion[J].Neuro Oncol,2012,14(10):1254-1264.
[18] Adisakwattana P,Suwandittakul N,Petmitr S,et al.ALCAM is a novel cytoplasmic membrane protein in tnf-α stimulated invasive cholangiocarcinoma cells[J].Asian Pac J Cancer Prev,2015,16(9):3849-3856.
[19] Fu C,Wang J,Xin X,et al.Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients[J].Exp Ther Med,2013,6(4):977-982.
[20] Hansen AG,Arnold SA,Jiang M,et al.ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone[J].Cancer Research,2014,74(5):1404-1415.
[21] Wong HL,Ng LPW,Koh SP,et al.Hotspot KRAS exon 2 mutations in CD166 positive colorectal cancer and colorectal adenoma cells[J].Oncotarget,2018,9(29):20426.
[22] 武会斌,王皇建,王云帅,等.CD68和CD166在结直肠癌组织中的表达及临床意义[J].河北医药,2023,45(3):348-352.
[23] Fujiwara K,Ohuchida Ki,Sada M,et al.CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells[J].PLoS One,2014,9(9):e107247.
[24] Yan M,Yang X,Wang L,et al.Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma[J].Mol Cell Proteomics,2013,12(11):3271-3284.

相似文献/References:

[1]朱清红,李德奎,罗 英.血清尿酸、β2微球蛋白和尿液轻链联合检测〖JZ〗在多发性骨髓瘤早期诊断中的应用[J].陕西医学杂志,2019,(9):1235.
　ZHU Qinghong,LI Dekui,LUO Ying..Combined detection of serum uric acid，β2 microglobulin and urine light chain〖JZ〗in early diagnosis of multiple myeloma[J].,2019,(12):1235.
[2]靳娟娟,姚 玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
　JIN Juanjuan,YAO Yu.Effect of MutT homologue-1 inhibitor on proliferation and apoptosis of multiple myeloma cells[J].,2021,50(12):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
[3]杜娟英,薛海鲸.多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J].陕西医学杂志,2022,51(12):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
　DU Juanying,XUE Haijing.Detection and clinical significance of serum miR-424,sRAGE and CD117 in patients with multiple myeloma[J].,2022,51(12):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
[4]刘虹伶,王美佳,晏青霞.多发性骨髓瘤患者血清β2-微球蛋白、肿瘤坏死因子-α、乳酸脱氢酶检测及临床意义[J].陕西医学杂志,2024,(3):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
　LIU Hongling,WANG Meijia,YAN Qingxia.Detection and clinical significance of serum β2-microglobulin,tumor necrosis factor-α and lactate dehydrogenase in patients with multiple myeloma[J].,2024,(12):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
[5]滕 远,李莉娟,张连生.髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展[J].陕西医学杂志,2024,(6):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
　TENG Yuan,LI Lijuan,ZHANG Liansheng.Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma[J].,2024,(12):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
[6]赵思捷,余 航,党珮珠,等.多发性骨髓瘤患者合并心包积液危险因素分析及列线图预测模型构建[J].陕西医学杂志,2024,(12):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]
　ZHAO Sijie,YU Hang,DANG Peizhu,et al.Risk factors of multiple myeloma patients with pericardial effusion and construction of nomogram prediction model[J].,2024,(12):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]

备注/Memo

备注/Memo:
基金项目:安徽省自然科学基金资助项目(2208085MH217); 安徽医科大学科研基金资助项目(2022XKJ212)
更新日期/Last Update: 2023-12-05